Related Experiment Video

Updated: Apr 19, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study

Lionel Piroth1, Stanislas Pol2, Patrick Miailhes3

  • 1Infectious Diseases Department, CHU and UMR 1347, University of Burgundy, Dijon, France.

Liver International : Official Journal of the International Association for the Study of the Liver
|January 7, 2015
PubMed

Insights

Management of chronic hepatitis B (CHB) in HIV-positive patients has improved, with better HBV DNA undetectability and reduced hepatocellular carcinoma risk. This is likely due to HAART and increased HBV therapy use, mitigating HIV

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Chronic hepatitis B (CHB) management and outcomes in HIV-positive versus HIV-negative patients are compared.
  • HIV-positive patients often present with more comorbidities and advanced disease markers.

Purpose of the Study:

  • To compare the management and evolution of CHB in HIV-positive and HIV-negative patients.
  • To assess the impact of HIV on CHB progression and treatment outcomes.

Main Methods:

  • Retrospective analysis of 709 patients with HBs antigenemia from 19 French centers.
  • Data collected via standardized questionnaires from the first visit onwards.

Main Results:

  • HIV-positive patients had less CHB assessment but received more HBV therapy (95.3% vs 56.8%) and achieved higher HBV undetectability (80.8% vs 55.1%).
  • Hepatocellular carcinoma was less frequent in HIV-positive patients (0.7% vs 4.7%).
  • Undetectable HBV was associated with longer HBV therapy and older age, not HIV status.

Conclusions:

  • Despite assessment gaps, HIV's negative impact on CHB evolution is diminishing.
  • Highly active antiretroviral therapy (HAART) and increased HBV treatment likely improve CHB outcomes in coinfected patients.
Abstract

Keywords:
HBVHIVcirrhosisentecavirhepatocellular carcinomatenofovir

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

3.1K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
266
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
47
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
364
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
1